Sign In
Buy FENC
$9.14
-0.84 (-8.42%)
At Close: Jun 03, 2026
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
07:04am, Thursday, 29'th Feb 2024
~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
05:55am, Thursday, 01'st Feb 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S.
Recent Price Trend in Adherex Technologies Inc. (FENC) is Your Friend, Here's Why
10:32am, Thursday, 21'st Dec 2023
Adherex Technologies Inc. (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma
Fennec Announces Incremental $5 Million Investment from Petrichor
05:55am, Tuesday, 05'th Dec 2023
~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK® Rollout ~ ~ Facilitates Market Expansion into the Adole
Wall Street Analysts Think Adherex Technologies Inc. (FENC) Could Surge 81%: Read This Before Placing a Bet
11:17am, Monday, 27'th Nov 2023
The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 81% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Fennec Pharmaceuticals Expands Possible TAM Significantly
06:24pm, Thursday, 09'th Nov 2023
Fennec Pharmaceuticals is a commercial-stage biotech company with a single drug, PEDMARK®, which is FDA-approved to reduce the risk of hearing loss in pediatric cancer patients. The company faced cha
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
04:50pm, Thursday, 09'th Nov 2023
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa
Fennec Pharmaceuticals Inc. (FENC) Q3 2023 Earnings Call Transcript
11:19am, Monday, 06'th Nov 2023
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rosty Raykov - Chief Executive Off
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
08:16am, Monday, 06'th Nov 2023
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.31 per share a year ago.
Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023
06:45am, Monday, 30'th Oct 2023
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
05:59am, Thursday, 07'th Sep 2023
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp
Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Call Transcript
09:00am, Sunday, 06'th Aug 2023
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rostislav Raykov - Chief Executive O
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
09:00am, Thursday, 03'rd Aug 2023
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.
Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
05:30am, Monday, 31'st Jul 2023
RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp
Fennec Pharmaceuticals Inc. (FENC) Q1 2023 Earnings Call Transcript
11:34pm, Saturday, 13'th May 2023
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rostislav Raykov - Chief Executive Off
